南京市鼓楼区集庆门大街 270 号苏宁环球国际中心 43 层 电话：025-85803866 传真：025-85803680 邮编：210000 北京国枫（南京）律师事务所 关于前沿生物药业（南京）股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]H0027 号 致：前沿生物药业（南京）股份有限公司（贵公司） 北京国枫（南京）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《律师事务所从事证券法律业务管理 办法》（以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试 行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性 文件及《前沿生物药业（南京）股份有限公司章程》（以下简称"《公司章程》"）的规 定，就本次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及 表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律 ...

证券代码：688221 证券简称：前沿生物 公告编号：2025-016 前沿生物药业（南京）股份有限公司 2024年年度股东大会会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 23 日 （二） 股东大会召开的地点：南京嘉悦·印湖酒店（南京市江宁开发区丽泽路 5 号门） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 93 | | --- | --- | | 普通股股东人数 | 93 | | 2、出席会议的股东所持有的表决权数量 | 173,180,166 | | 普通股股东所持有表决权数量 | 173,180,166 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 46.2333 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 46.233 ...

Core Insights - Chengdu East New Area is leveraging scene innovation to enhance the transformation of results, promoting deep integration of technological and industrial innovation [1][2] - The "front store, back factory" model implemented by Chengdu Anke Xing Technology Co., Ltd. in Chengdu Future Medical City signifies a new development model that reshapes the industrial ecosystem and stimulates new consumption potential [1] Group 1: Scene Innovation and Industrial Ecosystem - The unveiling of the "front store, back factory" innovation scene marks a significant step in reshaping the industrial ecosystem within the park, aiming to cultivate new productive forces and stimulate consumption [1] - The model integrates research, production, and consumer experience, allowing for direct consumer access to newly developed technological skincare products, effectively reducing the distance from laboratory to shelf [1] Group 2: Enterprise Support System - Chengdu Future Medical City has established a robust "We Hello" enterprise service system, focusing on innovation-driven and service-enabled approaches, which includes a comprehensive "1+2+3+N" service framework [2] - The service system provides a three-tier response mechanism to meet the lifecycle needs of enterprises, ensuring precise alignment between enterprise services and industrial demands [2] - Financial products like the "Future Medical Sci-Tech Loan" support startups by offering no-collateral, no-flow loans, facilitating technological innovation and industrial upgrades [2] Group 3: Future Development and Economic Growth - Chengdu Future Medical City plans to create more diverse innovation scenes and explore new pathways for technology transformation, aiming to inject new momentum into regional economic high-quality development [2]

中信证券股份有限公司 关于前沿生物药业（南京）股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为前沿生 物药业（南京）股份有限公司（以下简称"前沿生物"或"公司"或"上市公司"） 以简易程序向特定对象发行 A 股股票的保荐人，于 2022 年 7 月 8 日与公司签订 保荐协议，自签署保荐协议之日起，承接原保荐人瑞银证券有限责任公司尚未完 成的持续督导工作。根据《证券发行上市保荐业务管理办法》、《上海证券交易 所科创板股票上市规则》等相关规定，中信证券履行持续督导职责，并出具本持 续督导年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2024 年 9 月 4 日、2025 年 4 月 28 日对公司进行了现场检 查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责 ...

一、发行人基本情况 二、本次发行情况概述 中信证券股份有限公司关于 前沿生物药业（南京）股份有限公司持续督导 保荐总结报告书 保荐人编号：Z20374000 申报时间：2025 年 5 月 | 公司名称 | 前沿生物药业（南京）股份有限公司 | | --- | --- | | 证券代码 | 688468.SH | | 法定代表人 | DONG XIE | | 股本 | 374,578,653股 | | 成立时间 | 2013年1月15日 | | 注册地点 | 南京市江宁区科学园乾德路5号7号楼（紫金方山） | | 实际控制人 | DONG XIE | | 本次证券发行类型 | 以简易程序向特定对象发行A股股票 | | 本次证券上市时间 | 2022年9月22日 | | 年度报告披露时间 | 2022年度报告于2023年3月31日披露 | | | 2023年度报告于2024年3月30日披露 | | | 2024年度报告于2025年4月30日披露 | 根据中国证券监督管理委员会出具的《关于同意前沿生物药业（南京）股份 有限公司向特定对象发行股票注册的批复》（证监许可〔2022〕1823 号），同意 公司向特定对象 ...

会议资料 2025 年 5 月 证券代码：688221 证券简称：前沿生物 前沿生物药业（南京）股份有限公司 2024 年年度股东大会 一、 股东出席本次股东大会会议所产生的费用由其自行承担。本公司不向参加股东 大会的股东发放礼品，不负责安排参加股东大会股东的食宿及交通等事项，以平等原则 对待所有股东。 二、 为保证股东大会的严肃性和正常秩序，切实维护与会股东的合法权益，除出席 会议的股东（包括股东代理人，下同）、公司董事、监事、高级管理人员、见证律师及 董事会邀请的人员外，公司有权拒绝其他人员进入会场。 三、 会议开始后，由大会主持人宣布现场出席会议的股东人数及其所持有表决权的 股份总数，在此之后进入的股东无权参与现场投票表决。 1 目录 | 2024 | 年年度股东大会会议须知 3 | | | | --- | --- | --- | --- | | 2024 | 年年度股东大会会议议程 5 | | | | 2024 | 年年度股东大会会议议案 | 7 | | | 议案一 | 《关于公司<2024 | 年年度报告>及其摘要的议案》 | 7 | | 议案二 | 《关于公司<2024 | 年度财务决算报告>的议 ...

Group 1: Macro Insights - The Federal Reserve maintained interest rates and emphasized increasing uncertainty, with market expectations for rate cuts in June and July at 20% and 80% respectively, and a total of three cuts expected for the year [4] - The current economic environment presents a dual challenge of stagnation versus inflation, with short-term liquidity crises and long-term recession concerns [4] Group 2: TMT Sector Analysis - The TMT sector shows high levels of crowding, suggesting a cautious approach as the market may continue to favor lower-performing sectors [5] - The industry rotation model indicates that cyclical sectors like non-ferrous metals, steel, food and beverage, and building materials are in a strong trend with low crowding, while TMT remains crowded [5] Group 3: Coal Industry Overview - As of Q1 2025, the coal industry is experiencing a significant downturn, with coal prices returning to levels seen in early 2021, and the average price of Q5500 coal at 657 RMB/ton, down 111 RMB/ton since the beginning of the year [14][15] - The total profit of large coal enterprises in Q1 2025 was 803.8 billion RMB, a year-on-year decrease of 47.7%, with over half of coal companies reporting losses [17] - Major coal companies like China Shenhua and Shaanxi Coal have substantial cash reserves, indicating strong dividend-paying capabilities despite the industry's challenges [7][9] Group 4: Media Sector Performance - The media sector showed a significant recovery in Q1 2025, with notable performances in gaming and cinema, and a positive outlook for the year [22] - The film industry, particularly, is expected to benefit from a strong lineup of releases, although some major films underperformed [26] Group 5: Home Appliance and Electric Vehicle Industry - The electric two-wheeler market is expected to see growth driven by brand and channel advantages, with a projected increase in demand primarily from replacement sales [22][23] - The home appliance sector is focusing on expanding smart product offerings and enhancing international market presence, with significant revenue growth reported in smart home products [28] Group 6: Medical and Biopharmaceutical Sector - Companies like Xinhua Medical and Anjisi are showing steady growth, with Xinhua Medical reporting a slight increase in revenue and profit, while Anjisi's revenue grew by 25.14% in 2024 [36][38] - The biopharmaceutical sector is focusing on diversifying revenue streams and expanding into international markets, with significant growth expected in the coming years [35][40] Group 7: Investment Recommendations - Key recommendations include investing in leading coal enterprises like China Shenhua and Zhongmei Energy, as well as companies showing potential for recovery like Qinfa [19][20] - In the media sector, companies with strong content pipelines and market positions are recommended for investment [26]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Viewpoints - The company achieved a significant reduction in losses, with a total revenue of CNY 129.47 million in 2024, representing a year-on-year increase of 13.32%. The net loss attributable to shareholders was CNY 201.38 million, a reduction of CNY 127.58 million compared to the previous year [1][3] - The company is focusing on expanding the indications for its product Aikening, with new clinical trials approved for maintenance therapy and immune reconstitution failure, addressing a significant unmet clinical need in the HIV treatment space [2] - The company is actively exploring the small nucleic acid field for new drug development, with a candidate drug FB7013 for IgA nephropathy entering the IND-enabling stage and nine patent applications submitted to establish a technological moat [2] - The company is making breakthroughs in high-end generic drugs, with FB4001 expected to be approved in the US by 2025 and FB3002's application accepted for review, enhancing the company's revenue matrix [3] - Revenue forecasts for 2025-2027 are projected at CNY 161 million, CNY 190 million, and CNY 223 million, with year-on-year growth rates of 24.0%, 18.4%, and 17.2% respectively [3] Financial Summary - In 2024, the company reported total revenue of CNY 129.47 million, with a year-on-year growth rate of 13.32%. The net loss attributable to shareholders was CNY 201.38 million, a decrease of 38.8% from the previous year [5] - The projected revenues for 2025, 2026, and 2027 are CNY 161 million, CNY 190 million, and CNY 223 million, with corresponding growth rates of 24.0%, 18.4%, and 17.2% [5][11] - The latest diluted EPS for 2024 is expected to be CNY -0.54, with a projected improvement to CNY -0.49 in 2025 [5][11]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company achieved a significant reduction in losses, with a total revenue of 129.47 million yuan in 2024, representing a year-on-year increase of 13.32% [1] - The net profit attributable to shareholders was a loss of 201.38 million yuan, a reduction in loss by 127.58 million yuan compared to the previous year, attributed to cost reduction and efficiency improvements [1] - The company is focusing on expanding its revenue matrix through its main product, Aikening, and diversified business operations [1][2] Revenue Growth and Business Development - The company is actively promoting Aikening for new indications, with clinical trials for maintenance therapy and immune reconstitution failure approved by the National Medical Products Administration [2] - There is a significant unmet clinical need in the immune reconstitution failure area, with over 200,000 patients in China, indicating potential for future commercialization [2] - The company is exploring new technologies in the small nucleic acid field, with a candidate drug for IgA nephropathy, FB7013, entering the IND-enabling stage [2] High-End Generic Drugs and Future Projections - The company is making breakthroughs in high-end generic drugs, with FB4001 expected to be approved in the US by 2025 and FB3002's application accepted for review [3] - Revenue projections for 2025-2027 are 161 million yuan, 190 million yuan, and 223 million yuan, with year-on-year growth rates of 24.0%, 18.4%, and 17.2% respectively [3][5] - The net profit attributable to shareholders is projected to be -182 million yuan, -120 million yuan, and -176 million yuan for the same period [3][5] Financial Metrics - The company reported a revenue of 114 million yuan in 2023, with a growth rate of 34.8% [5] - The latest diluted EPS is projected to improve from -0.88 yuan in 2023 to -0.49 yuan in 2025 [5] - The company’s total market capitalization is approximately 3,206.39 million yuan, with a closing price of 8.56 yuan as of May 7 [6]

中信证券股份有限公司 关于前沿生物药业（南京）股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对前沿生物药业（南京）股份有限公司（以下简称"前沿生物"、 "上市公司"、"公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 周游、徐磊 （三）现场检查人员 周游、温志洋 （四）现场检查时间 2025 年 4 月 28 日 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 本次现场检查的手段主要包括资料查阅、访谈、现场查看等 ...